During year 4, huge progress has been done in the enrolment of patients in the clinical studies within the TransBioLine project to move forward in the identification of novel biomarkers that reliably indicate specific organ injury during drug development. To highlight, recruitment for the pancreatic injury working group has finally commenced at 3 centres, after several delays. Learning phase studies have been completed, and prospective recruitment for confirmatory phase studies is well underway for all teams.

WP1Pre-eclampsiaanti-VEGF
UZHenrollingenrolling
KUMapprovedapproved
UMA/SASenrolling-
UBERNsubmitted-
WP2DILIALFNAFLDMethotraxate
UNOTTenrollingenrollingenrollingenrolling
UZHenrolling---
KUMenrolling---
UMA/SASenrolling---
Landspitali enrolling---
APHPapproved---
UBERNsubmitted---
WP3MAP-1
ULIVsubmitted
KUMnot yet submitted
UMA/SASsubmitted
WP4VasculitidesAngioplasty  
UZHenrollingenrolling  
UMA/SASenrolling-  
WP5TBIMSChemoBrainNHV
Charité-completed completed completed
Pfizercompleted --enrolling
WP6NHV
Janssenenrolling

 

enrolling: trial is running, patient recruitment is underway
approved: ethical approval has been received, patients not yet being recruited
submitted: study awaiting ethical approval, documents submitted to local ethical committee
not yet submitted: documents will be submitted for ethical approval shortly
completed: patients no longer being recruited
-: not planned/not applicable